Starpharma, an Australia-based biotechnology company, announced on Wednesday that it has signed a new DEP(R) Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, New Jersey, USA.
This new DEP program will generate and evaluate additional DEP Antibody Drug Conjugates (ADCs). This new agreement follows an earlier DEP ADC agreement that Starpharma signed with MSD in February 2021, as well as an expanded DEP Research Agreement with another large US biopharmaceutical company in June 2022.
The company's DEP(R) ADCs have the capability to overcome the limitation of relatively low drug loading that is a feature of first-generation ADCs.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval